Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 MilliporeSigma Develops New CRISPR Genome Editing Method | Contract Pharma

What are you searching for?

Sign in
Breaking News

MilliporeSigma Develops New CRISPR Genome Editing Method

Aims to provide researchers with more experimental options and faster results

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

MilliporeSigma has developed a new genome editing tool designed to make CRISPR more efficient, flexible and specific, in an effort to provide researchers with more experimental options and faster results.

This new technique, called “proxy-CRISPR,” provides access to previously unreachable areas of the genome, according to the company. Most natural CRISPR systems, found in bacteria, cannot work in human cells without significant re-engineering. However, proxy-CRISPR provides a a new method to increase their usability without the need to re-engineer native CRISPR proteins. 

“With more flexible and easy-to-use genome editing technologies, there is greater potential in research, bioprocessing and novel treatment modalities,” said Udit Batra, chief executive officer, MilliporeSigma. “As a leader in genome editing, MilliporeSigma’s new technology is just one example of our commitment to solving challenges in the genome editing field, and we will continue to make CRISPR research a priority.”

CRISPR genome editing technology is helping to advance treatment options for some hard to treat medical conditions, including chronic illnesses and cancers for which there are limited or no treatment options.

The new technology is a follow-on to MilliporeSigma’s existing CRISPR applications. The company’s next suite of genome editing tools for the research community, to be launched later in 2017, will include new and modified versions of Cas and Cas-like proteins.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics